As leaders of eight of Canada’s provincial health and life sciences organizations, we are writing to express concerns about the PMPRB’s impending decision on the above-noted proposed Guidelines changes. We strongly believe you should postpone any decisions related to this initiative for several important reasons.
Read MoreBioTalent Canada today announced the kickoff of a $1.15M research study titled Building Resiliency and Sustainability for the Bio-economy to Withstand Disruption. The project, funded by the Future Skills Centre, which wraps up in September 2022, will leverage lessons learned from the pandemic to ensure long-term sustainability within Canada’s bio-economy.
Read MoreThis Japanese study, in combination with final data from the global Phase 2/3 study of the vaccine candidate, will be used to support an application for regulatory approval in Japan by March of 2022.
Read MoreAmorChem, BIOQuébec and CQDM, co-organizers of Sweet Pharma Day, are pleased to announce that HDAX Therapeutics is the winner of the 2021 edition. Sixteen Canadian startup companies (“Sweet 16”) selected by representatives from global pharma companies, made an elevator pitch in front of 150+ participants, who voted for HDAX Therapeutics as the winner of Sweet Pharma Day 2021 and of the $2,500 grand prize.
Read MoreLife science stakeholders, in particular, can play a central role in addressing current challenges, while delivering significant economic benefits including investment and jobs.
Read MoreMolecular Forecaster Inc. (MFI) is excited to announce it has secured funding to further develop its structure-based drug-design software, offer its research services, and expand into new niche drug targets.
Read MoreLaurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing LAU-7b, a first-in-class pro-resolving drug candidate, reported today topline results from its Phase 2 RESOLUTION clinical trial in hospitalized COVID-19 patients.
Read MoreToday, seven founding member organizations from the private, public, and not-for-profit sectors announced the establishment of the Inclusive Life Sciences Collaboration (Collaboration). The Collaboration aims to create a community of like-minded individuals and organizations committed to creating inclusive organizational cultures across the life sciences sector.
Read MoreAcasti Pharma Inc. today provided a business update and announced that the Nasdaq Stock Market (“Nasdaq”) has confirmed to Acasti that the Company has regained compliance with Nasdaq’s minimum bid price requirement.
Read MoreBELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced positive findings from a preplanned administrative interim analysis of the ongoing Phase 2b SOOTHE trial of BLU-5937, the Company’s highly selective P2X3 antagonist, in patients with refractory chronic cough (“RCC”).
Read MoreAugust 30, 2021, Montréal, Canada – Vantage BioTrials, a full service Contract Research Organization (CRO), is proud to have successfully managed, and completed approximately 12 months in advance, a Phase IV observational, multicentre, postmarketing study in adult patients with a clinical diagnosis of moderate-to-severe Hidradenitis suppurativa (HS).
Read MoreMONTREAL, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Theratechnologies, Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today the publication of data from its preclinical research of TH1902 for the treatment of sortilin-positive triple negative breast cancer (TNBC) in the peer-reviewed journal Cancer Science, confirming the in vivo efficacy and safety of TH1902 against TNBC through a SORT1 receptor-mediated mechanism.
Read MoreMONTREAL--(BUSINESS WIRE)--Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced that following the receipt of a No Objection Letter (NOL) from Health Canada on July 29, 2021, it has dosed the first volunteers with INV-202 in its first-in-human phase 1 clinical trial, which will evaluate the safety, tolerability and pharmacokinetics of this compound.
Read MoreMONTRÉAL, Aug. 31, 2021 /CNW Telbec/ - CellCarta and Olink Proteomics AB announced today a strategic collaboration to offer Olink® Target 96 & Target 48 to pharmaceutical and biotech customers, advancing targeted protein biomarker quantification in clinical studies.
Read MoreMontreal, Quebec, August 26, 2021 – Novartis Pharmaceuticals Canada Inc., in partnership with C2 International is hosting the first ever Biome Summit in Canada. A unique, collaborative multi-stakeholder platform, the Summit this year aims to address the pressing issue of cardiovascular disease across the country.
Read MoreMONTREAL, Aug. 24, 2021 /CNW/ - Incyte (Nasdaq: INCY) today announced that Health Canada has granted a Notice of Compliance with conditions for Minjuvi® (tafasitamab), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant (ASCT).
Read MoreMONTRÉAL, Aug. 17, 2021 /CNW Telbec/ - NuChem Sciences, a drug discovery in chemistry contract research organization (CRO) located in Montréal, today announced the acquisition of OmegaChem of Lévis, Québec. As a result of this transaction, the new group formed by the two companies becomes Canada's largest CRO in drug discovery in chemistry.
Read MoreMONTRÉAL, Aug. 10, 2021 /CNW/ - Today, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, announced a major milestone in Canada's strategy to rebuild the biomanufacturing and life sciences sector. The Government of Canada has established a memorandum of understanding (MOU) with leading COVID-19 vaccine developer Moderna, Inc. to build a state-of-the-art mRNA vaccine production facility in Canada.
Read MoreDARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced the final topline results of the DeCidE1 Phase 2 clinical trial evaluating maveropepimut-S (MVP-S, formerly known as DPX-Survivac) in subjects with advanced recurrent ovarian cancer.
Read MoreMONTRÉAL, Aug. 2, 2021 /CNW Telbec/ - The Fonds de solidarité FTQ is proud to announce an investment to support an ownership transfer of the French company EMKA Technologies ("EMKA") to Québec engineer and entrepreneur David Brunet. Mr. Brunet, who managed the Canadian subsidiary of the SCIREQ group, will take over the reins at EMKA as president and CEO on August 2.
Read More
